Can switching between two powerful drugs beat advanced breast cancer?
NCT ID NCT07151586
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests whether alternating two different targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) helps people with advanced HER2-low triple-negative breast cancer live longer compared to using just one drug alone. About 260 adults with metastatic or locally advanced cancer that cannot be removed by surgery will be randomly assigned to one of the two treatment plans. The goal is to see if the alternating approach improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
Villejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
institut Paoli calmette
Marseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.